Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Investigate Business Mastercard Choices for Better Rewards and Rewards - 2From Fledgling to Master: Self-awareness in a Side interest
- 3The Way to Business: Startup Illustrations Learned
- 4What is the 'Survivor 50' Challenge? Hidden immunity idols will be up for grabs in every U.S. state.
- 5Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing
- Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
- Massachusetts court hears arguments in lawsuit alleging Meta designed apps to be addictive to kids
- Is Chinese food truly flavorful?
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- ACA subsidies latest: Making sense of what's happening with health care after Republicans revolt, forcing a vote on funding extension
- Europe’s EV Boom Was Real in 2025. The Real Fight Starts In 2026
- Saturn shines with the waxing moon at sunset on Nov. 29
- Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- Exploring the Difficulties of Beginning a Family: Individual Experiences
